Clinical Trials Sponsored by Jazz Pharmaceuticals

Total 19503 results

Jazz Pharmaceuticals

Completed

Study to Assess Food Effect on Sativex Bioavailability

Food Effect

United Kingdom
Jazz Pharmaceuticals

Completed

Abuse Potential of Sativex

Evaluation of Abuse Potential of Sativex

Canada
Jazz Pharmaceuticals

Completed

Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex

Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19...

United Kingdom
Jazz Pharmaceuticals

Completed

A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury

Pain

United Kingdom
Jazz Pharmaceuticals

Completed

A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin

Pain | Multiple Sclerosis

United Kingdom
Jazz Pharmaceuticals

Completed

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Hepatic Impairment

United States
Jazz Pharmaceuticals

Completed

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Epilepsy | Dravet Syndrome

France, United States, United Kingdom, Poland
Jazz Pharmaceuticals

Terminated

Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder

Autism Spectrum Disorder

United States
Jazz Pharmaceuticals

Completed

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

Infantile Spasms

United States, Poland
Jazz Pharmaceuticals

Withdrawn

Investigation of Cognitive Outcomes With Cannabidiol Oral Solution (EPI-COG)

Lennox-Gastaut Syndrome
Jazz Pharmaceuticals

Completed

An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes (GWPCARE5)

Epilepsy | Dravet Syndrome | Lennox-Gastaut Syndrome
Jazz Pharmaceuticals

Completed

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Idiopathic Hypersomnia

France, Spain, United States, Belgium, United Kingdom, Poland, Czechia, Finland
Jazz Pharmaceuticals

Terminated

A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects

Healthy Volunteers
Jazz Pharmaceuticals

Completed

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related Changes

United States
Jazz Pharmaceuticals

Approved for marketing

A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

Small Cell Lung Cancer
Jazz Pharmaceuticals

Completed

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

Obstructive Sleep Apnea | Narcolepsy

United States, France, Canada, Germany, Netherlands, Finland
Jazz Pharmaceuticals

Completed

Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease

Fatty Liver

United Kingdom
Jazz Pharmaceuticals

Completed

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS)

United States
Jazz Pharmaceuticals

Approved for marketing

EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML (401)

Secondary AML

United States
Jazz Pharmaceuticals

Withdrawn

A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.

Renal Insufficiency | Kidney Disease
Jazz Pharmaceuticals

Terminated

A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis

Head and Neck Squamous Cell Carcinoma

United Kingdom
Jazz Pharmaceuticals

Withdrawn

A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer

Advanced Cancer
Jazz Pharmaceuticals

Withdrawn

An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

Spain
Jazz Pharmaceuticals

Withdrawn

A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel

Healthy | Anesthesia

United Kingdom
Jazz Pharmaceuticals

Completed

Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.

Fibromyalgia

Spain, United States, Netherlands, United Kingdom, France, Germany, Italy
Jazz Pharmaceuticals

Completed

Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

Fibromyalgia

United States
Jazz Pharmaceuticals

Completed

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

Narcolepsy

United States, France, Germany, Switzerland
Jazz Pharmaceuticals

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Biliary Tract Cancer | HER2 Gene Mutation

United States, Puerto Rico
Jazz Pharmaceuticals

Available

An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

HER2-Positive Advanced Biliary Tract Cancer

Spain, United States, France, Italy, United Kingdom
Jazz Pharmaceuticals

Active, not recruiting

A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

Essential Tremor

United States, Spain, Poland, Germany
Jazz Pharmaceuticals

Active, not recruiting

A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Jazz Pharmaceuticals

Completed

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

Autism Spectrum Disorder

United States, Spain, Germany, Canada, Australia, United Kingdom
Jazz Pharmaceuticals

Completed

An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy

Narcolepsy

United States
Jazz Pharmaceuticals

Active, not recruiting

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants

Healthy Participants

United States
Jazz Pharmaceuticals

Completed

A Study of JZP150 in Adults With Posttraumatic Stress Disorder

Post Traumatic Stress Disorder

United States
Jazz Pharmaceuticals

Active, not recruiting

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

HER2+/HR+ Breast Cancer

United States, Spain, Canada
Jazz Pharmaceuticals

Completed

Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis (RELEASE MSS1)

Spasticity in Participants With Multiple Sclerosis

Czechia, Poland
Jazz Pharmaceuticals

Terminated

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

Schizophrenia

United States, Spain, Poland, Serbia
Jazz Pharmaceuticals

Completed

Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis

Multiple Sclerosis | Spasticity

United Kingdom
Jazz Pharmaceuticals

Completed

A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.

Pain | Peripheral Neuropathy

United Kingdom
Jazz Pharmaceuticals

Completed

A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy

Pain | Diabetic Neuropathy

United Kingdom
Jazz Pharmaceuticals

Completed

A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis

Multiple Sclerosis | Detrusor Overactivity

United Kingdom
Jazz Pharmaceuticals

Completed

A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain

Pain | Peripheral Neuropathy

United Kingdom
Jazz Pharmaceuticals

Completed

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy (SPRAY)

Pain | Cancer | Palliative Care

United Kingdom
Jazz Pharmaceuticals

Completed

A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.

Pain | Peripheral Neuropathy

United Kingdom
Jazz Pharmaceuticals

Terminated

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis (RELEASE MSS3)

Multiple Sclerosis (MS)

United States, Poland, Czechia, United Kingdom, Romania
Jazz Pharmaceuticals

Completed

A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United Kingdom
Jazz Pharmaceuticals

Completed

A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis

Multiple Sclerosis | Neuropathic Pain

United Kingdom
Jazz Pharmaceuticals

Completed

A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain

Pain

United Kingdom
Jazz Pharmaceuticals

Completed

An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis

Multiple Sclerosis

United Kingdom

3

Subscribe